No Single Pharma Model For Commercialization of Biomarkers (View from a Companion Diagnostics Company) | Diaceutics

No Single Pharma Model For Commercialization of Biomarkers (View from a Companion Diagnostics Company)

October 12th, 2012

Richard Kennedy

Richard Kennedy of Almac Diagnostics and Queen’s University Belfast, writes that in his experience there is no one route to market for biomarkers in the personalized medicine space. Each pharmaceutical and diagnostic company has its own preferred model and, by focusing on companion diagnostic assays that will be used for the registration of a drug, their approaches can be broadly summarized in three models. 

In our experience. there is no one route to market for biomarkers in the personalized medicine space. Each pharmaceutical company and diagnostic company has its own preferred model.  If we focus on companion diagnostic assays that will be used for the registration of a drug the various approaches can be broadly summarized in three models:

  1. The pharmaceutical company has already identified a biomarker or in-licensed IP from elsewhere. In this case, the diagnostic company is seen as a service provider and is paid for the various stages of biomarker development and validation in the clinical trial process. In this model the diagnostic company is paid on a work-package and milestone agreement, rather than on a royalty basis.
  2. The diagnostic company has independently developed or in-licensed a biomarker and makes the IP available to a pharmaceutical company for the purpose of drug development. This arrangement typically involves a fee for access to the IP and an agreed royalty on the sale of the biomarker and potentially on drug sales (as these rely on the biomarker). This kind of agreement may also involve some paid service work around biomarker delivery within clinical trials.
  3. The pharmaceutical company and the diagnostic company identify and develop a biomarker as part of a clinical trial. In this model both partners own the IP and agree royalties going forward. As in model 2, this kind of agreement may also involve some paid service work around biomarker delivery within clinical trials. For smaller pharma/biotech companies a risk sharing strategy may be possible, but the diagnostic company will need to be confident in the chance of success for the drug.

Richard Kennedy is the Medical Director/CLIA Diagnostic Laboratory head at Almac Diagnostics and the McClay Professor of Experimental Cancer Medicine at Queen’s University Belfast.

Blogs

View all blogs

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Case Studies

View all case studies

Publications

September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...
View all publications
Facebook
Twitter
YouTube
LinkedIn